Cargando…
Case Report: Progression of a Silent Corticotroph Tumor to an Aggressive Secreting Corticotroph Tumor, Treated by Temozolomide. Changes in the Clinic, the Pathology, and the β-Catenin and α-SMA Expression
Clinically silent corticotroph tumors are usually macroadenomas that comprise 20% of ACTH tumors. They frequently progress to aggressive tumors with high recurrence, invasiveness, and on rare occasions, they may become hormonally active causing Cushing’s disease. Trustable biomarkers that can predic...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344046/ https://www.ncbi.nlm.nih.gov/pubmed/35928898 http://dx.doi.org/10.3389/fendo.2022.870172 |
_version_ | 1784761129278373888 |
---|---|
author | Demarchi, Gianina Perrone, Sofía Esper Romero, Gaela De Bonis, Cristian Casasco, Juan Pablo Sevlever, Gustavo Berner, Silvia Ines Cristina, Carolina |
author_facet | Demarchi, Gianina Perrone, Sofía Esper Romero, Gaela De Bonis, Cristian Casasco, Juan Pablo Sevlever, Gustavo Berner, Silvia Ines Cristina, Carolina |
author_sort | Demarchi, Gianina |
collection | PubMed |
description | Clinically silent corticotroph tumors are usually macroadenomas that comprise 20% of ACTH tumors. They frequently progress to aggressive tumors with high recurrence, invasiveness, and on rare occasions, they may become hormonally active causing Cushing’s disease. Trustable biomarkers that can predict their aggressive course, as well as their response to traditional or new therapies, are paramount. Aberrant β-Catenin expression and localization have been proposed as responsible for several malignancies including pituitary tumors. Nevertheless, the role of β-Catenin in the aggressive transformation of silent corticotropinomas and their response to Temozolomide salvage treatment have not been explored yet. In this work, we present a case of a silent corticotroph tumor that invaded cavernous sinus and compressed optic chiasm and, after a first total resection and tumor remission it recurred six years later as an aggressive ACTH-secreting tumor. This lesion grew with carotid compromise and caused Cushing’s signs. It required multiple medical treatments including Cabergoline, Ketoconazole, TMZ, and radiotherapy. Besides, other two surgeries were needed until it could be controlled. Interestingly, we found α-SMA vascular area reduction and differential β-Catenin cell localization in the more aggressive tumor stages characterized by high Ki-67 indexes and p53 expression. Our results may indicate a role of angiogenesis and β-Catenin trigged events in the pituitary tumor progression, which could in turn affect the response to TMZ and/or conventional treatments. These molecular findings in this unusual case could be useful for future management of aggressive pituitary tumors. |
format | Online Article Text |
id | pubmed-9344046 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93440462022-08-03 Case Report: Progression of a Silent Corticotroph Tumor to an Aggressive Secreting Corticotroph Tumor, Treated by Temozolomide. Changes in the Clinic, the Pathology, and the β-Catenin and α-SMA Expression Demarchi, Gianina Perrone, Sofía Esper Romero, Gaela De Bonis, Cristian Casasco, Juan Pablo Sevlever, Gustavo Berner, Silvia Ines Cristina, Carolina Front Endocrinol (Lausanne) Endocrinology Clinically silent corticotroph tumors are usually macroadenomas that comprise 20% of ACTH tumors. They frequently progress to aggressive tumors with high recurrence, invasiveness, and on rare occasions, they may become hormonally active causing Cushing’s disease. Trustable biomarkers that can predict their aggressive course, as well as their response to traditional or new therapies, are paramount. Aberrant β-Catenin expression and localization have been proposed as responsible for several malignancies including pituitary tumors. Nevertheless, the role of β-Catenin in the aggressive transformation of silent corticotropinomas and their response to Temozolomide salvage treatment have not been explored yet. In this work, we present a case of a silent corticotroph tumor that invaded cavernous sinus and compressed optic chiasm and, after a first total resection and tumor remission it recurred six years later as an aggressive ACTH-secreting tumor. This lesion grew with carotid compromise and caused Cushing’s signs. It required multiple medical treatments including Cabergoline, Ketoconazole, TMZ, and radiotherapy. Besides, other two surgeries were needed until it could be controlled. Interestingly, we found α-SMA vascular area reduction and differential β-Catenin cell localization in the more aggressive tumor stages characterized by high Ki-67 indexes and p53 expression. Our results may indicate a role of angiogenesis and β-Catenin trigged events in the pituitary tumor progression, which could in turn affect the response to TMZ and/or conventional treatments. These molecular findings in this unusual case could be useful for future management of aggressive pituitary tumors. Frontiers Media S.A. 2022-07-19 /pmc/articles/PMC9344046/ /pubmed/35928898 http://dx.doi.org/10.3389/fendo.2022.870172 Text en Copyright © 2022 Demarchi, Perrone, Esper Romero, De Bonis, Casasco, Sevlever, Berner and Cristina https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Demarchi, Gianina Perrone, Sofía Esper Romero, Gaela De Bonis, Cristian Casasco, Juan Pablo Sevlever, Gustavo Berner, Silvia Ines Cristina, Carolina Case Report: Progression of a Silent Corticotroph Tumor to an Aggressive Secreting Corticotroph Tumor, Treated by Temozolomide. Changes in the Clinic, the Pathology, and the β-Catenin and α-SMA Expression |
title | Case Report: Progression of a Silent Corticotroph Tumor to an Aggressive Secreting Corticotroph Tumor, Treated by Temozolomide. Changes in the Clinic, the Pathology, and the β-Catenin and α-SMA Expression |
title_full | Case Report: Progression of a Silent Corticotroph Tumor to an Aggressive Secreting Corticotroph Tumor, Treated by Temozolomide. Changes in the Clinic, the Pathology, and the β-Catenin and α-SMA Expression |
title_fullStr | Case Report: Progression of a Silent Corticotroph Tumor to an Aggressive Secreting Corticotroph Tumor, Treated by Temozolomide. Changes in the Clinic, the Pathology, and the β-Catenin and α-SMA Expression |
title_full_unstemmed | Case Report: Progression of a Silent Corticotroph Tumor to an Aggressive Secreting Corticotroph Tumor, Treated by Temozolomide. Changes in the Clinic, the Pathology, and the β-Catenin and α-SMA Expression |
title_short | Case Report: Progression of a Silent Corticotroph Tumor to an Aggressive Secreting Corticotroph Tumor, Treated by Temozolomide. Changes in the Clinic, the Pathology, and the β-Catenin and α-SMA Expression |
title_sort | case report: progression of a silent corticotroph tumor to an aggressive secreting corticotroph tumor, treated by temozolomide. changes in the clinic, the pathology, and the β-catenin and α-sma expression |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344046/ https://www.ncbi.nlm.nih.gov/pubmed/35928898 http://dx.doi.org/10.3389/fendo.2022.870172 |
work_keys_str_mv | AT demarchigianina casereportprogressionofasilentcorticotrophtumortoanaggressivesecretingcorticotrophtumortreatedbytemozolomidechangesintheclinicthepathologyandthebcateninandasmaexpression AT perronesofia casereportprogressionofasilentcorticotrophtumortoanaggressivesecretingcorticotrophtumortreatedbytemozolomidechangesintheclinicthepathologyandthebcateninandasmaexpression AT esperromerogaela casereportprogressionofasilentcorticotrophtumortoanaggressivesecretingcorticotrophtumortreatedbytemozolomidechangesintheclinicthepathologyandthebcateninandasmaexpression AT deboniscristian casereportprogressionofasilentcorticotrophtumortoanaggressivesecretingcorticotrophtumortreatedbytemozolomidechangesintheclinicthepathologyandthebcateninandasmaexpression AT casascojuanpablo casereportprogressionofasilentcorticotrophtumortoanaggressivesecretingcorticotrophtumortreatedbytemozolomidechangesintheclinicthepathologyandthebcateninandasmaexpression AT sevlevergustavo casereportprogressionofasilentcorticotrophtumortoanaggressivesecretingcorticotrophtumortreatedbytemozolomidechangesintheclinicthepathologyandthebcateninandasmaexpression AT bernersilviaines casereportprogressionofasilentcorticotrophtumortoanaggressivesecretingcorticotrophtumortreatedbytemozolomidechangesintheclinicthepathologyandthebcateninandasmaexpression AT cristinacarolina casereportprogressionofasilentcorticotrophtumortoanaggressivesecretingcorticotrophtumortreatedbytemozolomidechangesintheclinicthepathologyandthebcateninandasmaexpression |